• awesomeicons6/solid/lock 100% Secure Online Payments

Anti-Human Beta Site APP Cleaving Enzyme (CT) (BACE)

Leinco

Anti-Human Beta Site APP Cleaving Enzyme (CT) (BACE) (B362-GRP)

Products

Sort by arrow-down-short-wide arrow-up-short-wide
Cat #
Size
Price
Cat # Size
chevron-left chevron-right
of

Description

Accumulation of the amyloid-b (Ab) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer’s disease. Ab peptide is generated by proteolytic cleavage of the b-amyloid protein precursor (APP) at b- and g-sites by two proteases. APP is first cleaved by b-secretase, producing a soluble derivative of the protein and a membrane anchored 99-amino acid carboxy-terminal fragment (C99). The C99 fragment serves as substrate for g-secretase to generate the 4 kDa amyloid-b peptide, which is deposited in the brains of all suffers of Alzheimer’s disease. The long-sought b-secretase was recently identified by several groups independently and designated β-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2).1-4 BACE/Asp2 is a novel transmembrane aspartic protease and colocalizes with APP.

Specifications

Manufacturer Cat# B362
Concentration 0.5 mg/ml
Formulation This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Target Beta Site APP Cleaving Enzyme
Applications WB
Storage This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Protein Beta Site APP Cleaving Enzyme